Search results
Zepbound is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. Zepbound should be used with a reduced-calorie diet and increased physical activity.
2 bar graphs showing the percentage of adults who had ≥10% and ≥20% weight loss in the SURMOUNT-1 trial (Zepbound 10 mg and 15 mg vs placebo at 72 weeks). There were 636, 630, and 643 total adults for Zepbound 10 mg, 15 mg, and placebo, respectively.
8 lis 2023 · Zepbound™ (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off.
Zepbound ® (ZEHP-bownd) is an injectable prescription medicine that may help adults with obesity, or with excess weight (overweight) who also have weight-related medical problems, lose weight and keep it off. It should be used with a reduced-calorie diet and increased physical activity.
4 cze 2022 · In this 72-week trial in participants with obesity, 5 mg, 10 mg, or 15 mg of tirzepatide once weekly provided substantial and sustained reductions in body weight. (Supported by Eli Lilly;...
15 paź 2023 · In a co-primary endpoint, following the lead-in period, participants taking tirzepatide achieved an additional 21.1% mean weight loss. In a secondary endpoint, participants achieved a total mean weight loss of 26.6% (29.2 kg or 64.4 lb.) from study entry over 84 weeks.
24 cze 2023 · Lilly's SURMOUNT-2 results published in The Lancet show tirzepatide achieved a mean weight reduction of 15.7% at the highest dose (15 mg) in adults with obesity or overweight and type 2 diabetes. June 24, 2023. PDF Version. Detailed results presented at the American Diabetes Association's ® 83rd Scientific Sessions.
